In chronic myeloid leukaemia (CML), BCR-ABL can enhance USP7-induced deubiquitination of PTEN, which is conducive to nuclear rejection (57). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.